Group 1 - The core point of the article is that Junfeng Pharmaceutical has received approval for the injection of remimazolam benzenesulfonate from the National Medical Products Administration [1] - The company holds an 80% stake in its subsidiary, Yichang Junfeng Pharmaceutical Co., Ltd., which is responsible for the newly approved drug [1]

Core Viewpoint - The company has received approval for a new indication for its injectable remimazolam, which is expected to expand its market usage and positively impact sales [1][2]. Group 1: Drug Registration Details - The drug name is injectable remimazolam, with registration numbers 2025S02529 and 2025S02530 [1]. - The drug is classified as a chemical drug of category 2.4 and is produced by Yichang Renfu Pharmaceutical Co., Ltd., in which the company holds an 80% stake [1][2]. - The new indication approved is for use as a sedative during mechanical ventilation in intensive care [1][2]. Group 2: Development and Market Impact - The injectable remimazolam was co-developed with Germany's PAION and is a novel benzodiazepine derivative [2]. - The company invested approximately RMB 20 million in the project, and the projected market sales for 2024 are around RMB 250 million [2]. - The approval of the new indication is expected to broaden the product's application, potentially leading to increased revenue for the company [2].

证券代码：600079 证券简称：人福医药 编号：临 2025-101 人福医药集团股份公司关于注射用苯磺酸瑞马唑仑 增加适应症获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 人福医药集团股份公司（以下简称"公司"或"人福医药"）控股子公司宜昌人福 药业有限责任公司（以下简称"宜昌人福"，公司持有其80%的股权）近日收到国家药 品监督管理局核准签发的注射用苯磺酸瑞马唑仑的《药品注册证书》。现将批件主要内 容公告如下： 一、药品名称：注射用苯磺酸瑞马唑仑 六、申请事项：药品注册（境内生产） 七、药品批准文号：国药准字H20200006、国药准字H20227087 八、药品批准文号有效期：至2030年07月15日 九、上市许可持有人：宜昌人福药业有限责任公司 十、药品生产企业：宜昌人福药业有限责任公司 十一、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准增加适应症，新增适应症为："作为镇静药物用于重症 监护期间机械通气时的镇静"，发给药品注册证书。生产工艺 ...

Core Viewpoint - The company announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for injectable remimazolam from the National Medical Products Administration, marking a significant development in its product portfolio [1] Company Summary - Renfu Pharmaceutical holds an 80% stake in Yichang Renfu, which is involved in the development of the new drug [1] - The injectable remimazolam is a novel benzodiazepine developed in collaboration with the German company PAION, designed as an ultra-short-acting GABAa receptor agonist [1]

Group 1 - The core point of the article is that Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the injection of remimazolam benzenesulfonate, expanding its usage in sedation during mechanical ventilation in intensive care [1] - The newly approved indication for remimazolam benzenesulfonate is as a sedative for patients undergoing mechanical ventilation in intensive care, which is expected to broaden the product's application [1] - The future sales performance of this product may be influenced by industry policies and market conditions, indicating a level of uncertainty [1]

Group 1 - The core viewpoint of the news is that Renfu Pharmaceutical (600079) has shown a slight increase in stock price and a mixed performance in terms of capital flow and financial results [1] - As of August 22, 2025, Renfu Pharmaceutical's stock closed at 20.92 yuan, up 0.77%, with a turnover rate of 1.87% and a trading volume of 288,300 hands, amounting to 602 million yuan [1] - The net inflow of main funds today was 31.18 million yuan, accounting for 5.18% of the transaction amount, with significant contributions from large orders [1] Group 2 - For the first quarter of 2025, Renfu Pharmaceutical reported total operating revenue of 6.137 billion yuan, a year-on-year decrease of 3.61%, while net profit attributable to shareholders was 540 million yuan, an increase of 11.09% [1] - The company's current ratio is 1.494, quick ratio is 1.239, and debt-to-asset ratio is 42.59% [1] - Renfu Pharmaceutical Group was established in 1993 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 1.632 billion yuan [1] Group 3 - Renfu Pharmaceutical has made investments in 48 companies and participated in 18 bidding projects [2] - The company holds 364 trademark registrations and 266 patent registrations, along with 14 administrative licenses [2]

Market Overview - The Shanghai Composite Index closed at 3825.76 points, above the annual line, with an increase of 1.45% [1] - The total trading volume of A-shares reached 25,788.42 billion yuan [1] Stocks Breaking Annual Line - A total of 24 A-shares have surpassed the annual line today, with notable stocks including NovaStar, Nasda, and Zhaoshengwei, showing significant deviation rates of 7.19%, 4.59%, and 4.07% respectively [1] - Stocks with smaller deviation rates that just crossed the annual line include China National Materials, Kweichow Moutai, and Ruisi Kanda [1] Top Stocks by Deviation Rate - The top three stocks with the highest deviation rates are: - NovaStar (7.19% deviation, latest price 174.84 yuan) [1] - Nasda (4.59% deviation, latest price 26.55 yuan) [1] - Zhaoshengwei (4.07% deviation, latest price 84.73 yuan) [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Jin Yu Medical (3.28% deviation, latest price 31.57 yuan) [1] - China Merchants Heavy Industry (3.08% deviation, latest price 6.59 yuan) [1] - BOE Technology Group (2.18% deviation, latest price 4.18 yuan) [1]

Core Points - The Shanghai Composite Index closed at 3796.36 points, above the annual line, with a change of 0.67% [1] - The total trading volume of A-shares reached 15,306.58 billion yuan [1] - Thirteen A-shares have broken through the annual line today, with notable divergence rates for stocks like Nova Star Cloud, China Merchants Energy, and Zhaosheng Microelectronics [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3796.36 points, reflecting a 0.67% increase [1] - Total A-share trading volume is reported at 15,306.58 billion yuan [1] Stocks Breaking Through Annual Line - Notable stocks that have surpassed the annual line include: - Nova Star Cloud (Code: 301589) with a divergence rate of 8.66% and a daily increase of 10.32% [1] - China Merchants Energy (Code: 601872) with a divergence rate of 2.92% and a daily increase of 5.96% [1] - Zhaosheng Microelectronics (Code: 300782) with a divergence rate of 2.43% and a daily increase of 4.21% [1] Additional Stocks with Minor Divergence - Other stocks that have recently crossed the annual line with smaller divergence rates include: - Wanli Stone (Code: 002785) with a divergence rate of 1.20% [1] - Wanhua Chemical (Code: 600309) with a divergence rate of 1.18% [1] - Weisheng Information (Code: 688100) with a divergence rate of 1.11% [1] - Others include Tongwei Co., Newpoint Software, Renfu Pharmaceutical, and Yilian Network with minor divergence rates [1]

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index above the annual line, indicating a potential bullish trend in the market [1] Group 1: Market Performance - As of 10:31 AM today, the Shanghai Composite Index is at 3784.84 points, with a change of 0.36% [1] - The total trading volume of A-shares today is 1,091.82 billion yuan [1] Group 2: Stocks Breaking Annual Line - Thirteen A-shares have surpassed the annual line today, with notable stocks including Nova Star Cloud, Zhaosheng Micro, and China Merchants Energy, showing significant deviation rates of 7.63%, 3.61%, and 2.46% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Wanhua Chemical, Ruisi Kanda, and Renfu Pharmaceutical [1] Group 3: Individual Stock Performance - Nova Star Cloud (301589) has a daily increase of 9.27% and a trading turnover rate of 5.25%, with a latest price of 175.57 yuan and a deviation rate of 7.63% [1] - Zhaosheng Micro (300782) increased by 5.42% with a turnover rate of 3.90%, latest price at 84.36 yuan and a deviation rate of 3.61% [1] - China Merchants Energy (601872) rose by 5.48%, with a turnover rate of 1.84%, latest price at 6.55 yuan and a deviation rate of 2.46% [1]

Market Overview - The Shanghai Composite Index is at 3781.13 points, above the annual line, with a change of 0.40% [1] - The total trading volume of A-shares is 1,193.158 billion yuan [1] Stocks Breaking Annual Line - A total of 31 A-shares have surpassed the annual line today, with notable stocks including Meihua Medical, *ST Aowei, and Pianzaihuang, showing divergence rates of 14.13%, 2.94%, and 2.77% respectively [1] - Stocks with smaller divergence rates that have just crossed the annual line include China Wuyi, Huilun Crystal, and Zhuoshengwei [1] Top Stocks by Divergence Rate - Meihua Medical (301363) has a significant increase of 17.30% with a turnover rate of 23.04% and a divergence rate of 14.13% [1] - *ST Aowei (002231) increased by 3.12% with a turnover rate of 7.79% and a divergence rate of 2.94% [1] - Pianzaihuang (600436) rose by 3.70% with a turnover rate of 1.03% and a divergence rate of 2.77% [1] Additional Notable Stocks - Tongrentang (600085) increased by 1.93% with a divergence rate of 1.77% [1] - Maire Medical (300760) rose by 3.40% with a divergence rate of 1.53% [1] - Other stocks with minor divergence rates include Aima Technology (603529) and China Railway Construction (601186) with divergence rates of 1.06% and 0.96% respectively [1]